Weighted log-odds pooling of 5 agent estimates (research 49% (w=1.5); quant 67% (w=0.8); market 41% (w=0.6); sentiment 61% (w=0.5); historian 35% (w=0.7)), shrunk toward the science base rate, yields 48% — an edge of +7% versus the market at 41%.
Will a CRISPR-based therapy receive a new FDA approval this year?
Will a new heaviest element be confirmed this year?
How much the forecast would move if each signal were removed — leave-one-out over the real pipeline (baked at snapshot time).
One lead candidate reported a partial clinical hold.
Two candidates have PDUFA dates inside the window.
The first CRISPR approval established a regulatory template.
Every forecast is an argument. Seven agents deliberate; the skeptic attacks; synthesis pools.
The evidence base (2 supporting, 1 opposing signals) supports the event. The single strongest signal: Two candidates have PDUFA dates inside the window.
Of 2 comparable resolved events, 1 resolved YES (similarity-weighted rate 67%). Monte Carlo over the posterior gives a 90% credible interval of 34%-93%, and 90% of simulations land above the market's 41%.
Prediction markets price YES at 41¢ on $220,000 volume with low liquidity — an implied 41% probability. Thin liquidity means the price can be moved by few traders; treated as a weak prior.
Public sentiment runs 70% positive with increasing momentum. Sentiment is a weak standalone predictor, so it enters the pool at low weight.
Historically, science questions of this shape resolve YES about 30% of the time. With a 365-day horizon, the base rate pulls the current market read down to 35%.
The pipeline is above the market (50% vs 41%) — before trusting that edge, weigh: One lead candidate reported a partial clinical hold. Scientific milestones fail silently — a single unreplicated result can reset the clock.
Weighted log-odds pooling of 5 agent estimates (research 49% (w=1.5); quant 67% (w=0.8); market 41% (w=0.6); sentiment 61% (w=0.5); historian 35% (w=0.7)), shrunk toward the science base rate, yields 48% — an edge of +7% versus the market at 41%.
Signals ingested for this question, by impact.
Two candidates have PDUFA dates inside the window.
Pipeline · impact 0.8 · Oct 19
The first CRISPR approval established a regulatory template.
Precedent · impact 0.6 · Oct 19
One lead candidate reported a partial clinical hold.
Trial risk · impact 0.6 · Nov 3